Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Succinic Acid Firms Strike Royalty Deal
by Alex Scott
January 18, 2016
| A version of this story appeared in
Volume 94, Issue 3
The succinic acid maker BioAmber has agreed to pay Reverdia royalties for the right to use certain intellectual property for making the biobased chemical. Reverdia is a joint venture between DSM and Roquette. The parties aren’t disclosing the technology in question or the amount of money that will change hands. The agreement is a “constructive solution” that avoids confrontation and enables both firms to continue to use their own yeast-based routes to succinic acid, says BioAmber CEO Jean-François Huc.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter